Buntanetap (Posiphen)
Alzheimer's Disease
Key Facts
About Annovis Bio
Annovis Bio is a neuroscience-focused biotech founded in 2008 with a mission to halt nerve cell death in neurodegenerative disorders. Its core technology centers on buntanetap, a small molecule that inhibits the production of neurotoxic proteins like amyloid-beta, tau, and alpha-synuclein, aiming to restore axonal transport and synaptic function. The company is advancing late-stage clinical programs for Alzheimer's and Parkinson's disease, positioning itself as a potential next-generation treatment option in a challenging therapeutic area with high unmet need.
View full company profileAbout Annovis Bio
Annovis Bio is a neuroscience-focused biotech founded in 2008 with a mission to halt nerve cell death in neurodegenerative disorders. Its core technology centers on buntanetap, a small molecule that inhibits the production of neurotoxic proteins like amyloid-beta, tau, and alpha-synuclein, aiming to restore axonal transport and synaptic function. The company is advancing late-stage clinical programs for Alzheimer's and Parkinson's disease, positioning itself as a potential next-generation treatment option in a challenging therapeutic area with high unmet need.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |